Managed Healthcare Executive January 31, 2023
Amgen says it will sell the first biosimilar to Humira on the U.S. market at two prices.
The era of Humira (adalimumab) biosimilars in the U.S. is upon us.
Amgen announced this morning that it is selling Amjevita (adalimumab-atto), the first biosimilar to Humira (adalimumab). Perhaps as many as nine other biosimilar’s AbbVie’s blockbuster drug may come on the market this year.
Although the FDA approved Amjevita in September 2016, patent litigation and legal agreements between AbbVie and Amgen and other biosimilar makers have kept the approved biosimilars off the U.S. market till now.
Amgen said in this morning’s announcement that it is pricing its biosimilar at two prices: a wholesale acquisition cost (WAC) price that is...
Today's Sponsors
Today's Sponsor